Design Therapeutics, Inc. Stock-Based Compensation
Design Therapeutics, Inc. (DSGN) reported Stock-Based Compensation of $7.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-03
- Design Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.87M, a 2.96% decline year-over-year.
- Design Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.92M, a 10.88% increase year-over-year.
- Design Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.44M, a 1.04% decline year-over-year.
- Design Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.59M, a 15.14% increase year-over-year.
- Design Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $14.55M, a 11.30% increase from fiscal 2024.
- Design Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $13.07M, a 0.12% decline from fiscal 2023.
- Design Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $13.09M, a 19.80% increase from fiscal 2022.
- Design Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $10.93M, a 132.99% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $7.79M 10-Q · filed 2026-08-03 | $11.23M derived: sum of 3 quarters · filed 2026-08-03 | $14.82M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $3.92M 10-Q · filed 2026-04-28 | $7.36M derived: sum of 2 quarters · filed 2026-04-28 | $10.95M derived: sum of 3 quarters · filed 2026-04-28 | $14.93M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $7.03M derived: sum of 2 quarters · filed 2026-03-09 | $11.01M derived: sum of 3 quarters · filed 2026-08-03 | $14.55M 10-K · filed 2026-03-09 |
| 2025-09-30 | $3.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $7.58M derived: sum of 2 quarters · filed 2026-08-03 | $11.11M 10-Q · filed 2025-11-05 | $14.59M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $7.52M 10-Q · filed 2026-08-03 | $10.99M derived: sum of 3 quarters · filed 2026-08-03 | $14.11M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $3.54M 10-Q · filed 2026-04-28 | $7.01M derived: sum of 2 quarters · filed 2026-04-28 | $10.13M derived: sum of 3 quarters · filed 2026-04-28 | $13.43M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $3.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $6.59M derived: sum of 2 quarters · filed 2026-03-09 | $9.89M derived: sum of 3 quarters · filed 2026-03-09 | $13.07M 10-K · filed 2026-03-09 |
| 2024-09-30 | $3.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $6.42M derived: sum of 2 quarters · filed 2025-11-05 | $9.60M 10-Q · filed 2025-11-05 | $12.32M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $6.48M 10-Q · filed 2025-08-07 | $9.21M derived: sum of 3 quarters · filed 2025-08-07 | $12.43M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $3.18M 10-Q · filed 2025-05-07 | $5.91M derived: sum of 2 quarters · filed 2025-05-07 | $9.13M derived: sum of 3 quarters · filed 2025-05-07 | $12.85M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $5.94M derived: sum of 2 quarters · filed 2025-03-10 | $9.66M derived: sum of 3 quarters · filed 2025-03-10 | $13.09M 10-K · filed 2025-03-10 |
| 2023-09-30 | $3.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.94M derived: sum of 2 quarters · filed 2024-11-07 | $10.36M 10-Q · filed 2024-11-07 | $13.44M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $7.14M 10-Q · filed 2024-08-05 | $10.22M derived: sum of 3 quarters · filed 2024-08-05 | $13.09M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $3.43M 10-Q · filed 2024-05-08 | $6.50M derived: sum of 2 quarters · filed 2024-05-08 | $9.37M derived: sum of 3 quarters · filed 2024-05-08 | $11.99M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $5.95M derived: sum of 2 quarters · filed 2024-03-19 | $8.56M derived: sum of 3 quarters · filed 2024-03-19 | $10.93M 10-K · filed 2024-03-19 |
| 2022-09-30 | $2.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $5.49M derived: sum of 2 quarters · filed 2023-11-13 | $7.85M 10-Q · filed 2023-11-13 | $9.40M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $4.98M 10-Q · filed 2023-08-14 | $6.53M derived: sum of 3 quarters · filed 2023-08-14 | $7.78M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $2.36M 10-Q · filed 2023-05-09 | $3.92M derived: sum of 2 quarters · filed 2023-05-09 | $5.16M derived: sum of 3 quarters · filed 2023-05-09 | $6.40M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $2.80M derived: sum of 2 quarters · filed 2023-03-14 | $4.04M derived: sum of 3 quarters · filed 2023-03-14 | $4.69M 10-K · filed 2023-03-14 |
| 2021-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.49M derived: sum of 2 quarters · filed 2022-11-03 | $3.13M 10-Q · filed 2022-11-03 | $3.55M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.89M 10-Q · filed 2022-08-08 | $2.31M derived: sum of 3 quarters · filed 2022-08-08 | $2.33M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $647.00K 10-Q · filed 2022-05-09 | $1.07M derived: sum of 2 quarters · filed 2022-05-09 | $1.08M derived: sum of 3 quarters · filed 2022-05-09 | $1.09M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $436.00K derived: sum of 2 quarters · filed 2022-03-10 | $446.00K derived: sum of 3 quarters · filed 2022-03-10 | $450.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $25.00K derived: sum of 2 quarters · filed 2021-11-09 | $29.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $14.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $4.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |